NO310222B1 - Anvendelse av kitosan og et polysakkarid i forbindelse med sårheling - Google Patents
Anvendelse av kitosan og et polysakkarid i forbindelse med sårheling Download PDFInfo
- Publication number
- NO310222B1 NO310222B1 NO19970214A NO970214A NO310222B1 NO 310222 B1 NO310222 B1 NO 310222B1 NO 19970214 A NO19970214 A NO 19970214A NO 970214 A NO970214 A NO 970214A NO 310222 B1 NO310222 B1 NO 310222B1
- Authority
- NO
- Norway
- Prior art keywords
- chitosan
- film
- heparin
- polysaccharide
- tissue
- Prior art date
Links
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 44
- 150000004676 glycans Chemical class 0.000 title claims abstract description 13
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 13
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 13
- 230000029663 wound healing Effects 0.000 title claims abstract description 6
- 229920000669 heparin Polymers 0.000 claims abstract description 29
- 229960002897 heparin Drugs 0.000 claims abstract description 27
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- 229920002971 Heparan sulfate Polymers 0.000 claims abstract description 7
- 238000006640 acetylation reaction Methods 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 229960000633 dextran sulfate Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 5
- 229920002307 Dextran Polymers 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 229910021653 sulphate ion Inorganic materials 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 31
- 208000027418 Wounds and injury Diseases 0.000 description 28
- 206010052428 Wound Diseases 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 239000000499 gel Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 230000035876 healing Effects 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000021736 acetylation Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000007547 defect Effects 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000003815 abdominal wall Anatomy 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 210000002435 tendon Anatomy 0.000 description 5
- 229920002101 Chitin Polymers 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 210000000651 myofibroblast Anatomy 0.000 description 4
- 231100000241 scar Toxicity 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 206010063560 Excessive granulation tissue Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 210000001126 granulation tissue Anatomy 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- IINOLFPQEZQVMB-UHFFFAOYSA-N ethanol;1,2-xylene Chemical group CCO.CC1=CC=CC=C1C IINOLFPQEZQVMB-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 229920004937 Dexon® Polymers 0.000 description 1
- 208000001708 Dupuytren contracture Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 210000005033 mesothelial cell Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- -1 tubes or tubes Substances 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9402529A SE9402529D0 (sv) | 1994-07-19 | 1994-07-19 | Anti-adherensmedel |
| PCT/SE1995/000856 WO1996002258A1 (en) | 1994-07-19 | 1995-07-13 | Anti-adhesion agent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO970214L NO970214L (no) | 1997-01-17 |
| NO970214D0 NO970214D0 (no) | 1997-01-17 |
| NO310222B1 true NO310222B1 (no) | 2001-06-11 |
Family
ID=20394769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19970214A NO310222B1 (no) | 1994-07-19 | 1997-01-17 | Anvendelse av kitosan og et polysakkarid i forbindelse med sårheling |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP0772446B1 (ru) |
| JP (1) | JP4033485B2 (ru) |
| KR (1) | KR100395723B1 (ru) |
| CN (1) | CN1157569A (ru) |
| AT (1) | ATE226439T1 (ru) |
| AU (1) | AU708758B2 (ru) |
| BR (1) | BR9508323A (ru) |
| CA (1) | CA2194476C (ru) |
| CZ (1) | CZ287692B6 (ru) |
| DE (1) | DE69528654T2 (ru) |
| DK (1) | DK0772446T3 (ru) |
| ES (1) | ES2180649T3 (ru) |
| FI (1) | FI970201A (ru) |
| HU (1) | HUT77606A (ru) |
| IS (1) | IS1794B (ru) |
| MX (1) | MX9700442A (ru) |
| NO (1) | NO310222B1 (ru) |
| NZ (1) | NZ290218A (ru) |
| RU (1) | RU2155592C2 (ru) |
| SE (1) | SE9402529D0 (ru) |
| WO (1) | WO1996002258A1 (ru) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9402531L (sv) * | 1994-07-19 | 1996-01-20 | Medicarb Ab | Sårläkningsmedel |
| NL1011680C2 (nl) | 1999-03-26 | 2000-09-27 | Nutricia Nv | Voedingssamenstellen die licht negatief geladen, niet-verteerbare polysacchariden bevatten en gebruik ervan voor het verminderen van transport door tight junctions. |
| US6645947B1 (en) * | 1999-05-20 | 2003-11-11 | Chitogenics, Inc. | Adhesive N, O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins |
| SE523243C3 (sv) * | 1999-09-28 | 2004-05-26 | Medicarb Ab | Antimikrobiellt preparat för behandling och profylax |
| ES2169681B1 (es) * | 2000-08-10 | 2003-10-01 | Osfarma S L | Metodo de produccion de filmes de quitosan con una alta capacidad de adherencia celular, producto obrenido y aplicaciones. |
| KR20020066024A (ko) * | 2001-02-08 | 2002-08-14 | 굿젠 주식회사 | 수용성 키토산과 헤파린으로 이루어진 상처 치유 촉진연고 조성물과 필름 및 제품 |
| JP2004525954A (ja) * | 2001-04-12 | 2004-08-26 | メディカーブ・アクチエボラーグ | 発泡性固体組成物 |
| SE522529C2 (sv) | 2001-04-12 | 2004-02-17 | Medicarb Ab | Effervescent fastämneskomposition innefattande som aktiv komponent kitosan, dess derivat och salter därav, användning samt framställning därav |
| US7332179B2 (en) | 2003-12-12 | 2008-02-19 | Kimberly-Clark Worldwide, Inc. | Tissue products comprising a cleansing composition |
| US7642395B2 (en) | 2004-12-28 | 2010-01-05 | Kimberly-Clark Worldwide, Inc. | Composition and wipe for reducing viscosity of viscoelastic bodily fluids |
| US9441030B2 (en) * | 2007-02-23 | 2016-09-13 | Sk Chemicals Co., Ltd. | Process for producing and purifying factor VIII and its derivatives |
| NZ583819A (en) * | 2007-08-28 | 2012-08-31 | Medtronic Xomed Inc | Polymer comprising a dicarboxy-derivatised chitosan polymer cross-linked to an aldehyde-derivatised dextran polymer useful for preventing tissue adhesion and for promoting wound healing |
| PL235185B1 (pl) | 2008-07-02 | 2020-06-01 | Univ Jagiellonski | Polimer chitozanowy do zastosowania do usuwania heparyny |
| AU2010259284A1 (en) * | 2009-06-10 | 2011-12-15 | Exthera Ab | Use of a composition for the treatment of mucositis |
| EP3003026B1 (en) * | 2013-03-14 | 2019-07-17 | Tricol Biomedical, Inc. | Biocompatible and bioabsorbable derivatized chitosan compositions |
| CN103341217B (zh) * | 2013-06-13 | 2015-05-06 | 上海大学 | 一种用于防止手术后组织粘连的薄膜的制备方法 |
| KR101664444B1 (ko) * | 2013-12-13 | 2016-10-12 | 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 | 생분해성 의료용 접착제 또는 실란트 조성물 |
| CN106362221B (zh) * | 2016-09-30 | 2019-06-21 | 天津大学 | 一种具有抑菌促愈合功能的防粘连材料及其制备方法 |
| KR200490615Y1 (ko) | 2016-10-20 | 2020-01-13 | 주식회사 인트로컴퍼니 | 사용자 맞춤형 캘린더 |
| EP3787593A1 (en) * | 2018-05-04 | 2021-03-10 | Bonoss Medical Aktiebolag | A composition for reduction of scar formation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4326532A (en) * | 1980-10-06 | 1982-04-27 | Minnesota Mining And Manufacturing Company | Antithrombogenic articles |
| JPS61253065A (ja) * | 1985-05-02 | 1986-11-10 | 片倉チツカリン株式会社 | キトサン誘導体およびコラ−ゲンの複合材の医用材料およびその製造法 |
-
1994
- 1994-07-19 SE SE9402529A patent/SE9402529D0/xx unknown
-
1995
- 1995-07-13 CA CA002194476A patent/CA2194476C/en not_active Expired - Fee Related
- 1995-07-13 CZ CZ1997139A patent/CZ287692B6/cs not_active IP Right Cessation
- 1995-07-13 EP EP95926564A patent/EP0772446B1/en not_active Expired - Lifetime
- 1995-07-13 NZ NZ290218A patent/NZ290218A/xx unknown
- 1995-07-13 DK DK95926564T patent/DK0772446T3/da active
- 1995-07-13 AU AU30894/95A patent/AU708758B2/en not_active Ceased
- 1995-07-13 MX MX9700442A patent/MX9700442A/es unknown
- 1995-07-13 AT AT95926564T patent/ATE226439T1/de not_active IP Right Cessation
- 1995-07-13 KR KR1019970700337A patent/KR100395723B1/ko not_active IP Right Cessation
- 1995-07-13 HU HU9700161A patent/HUT77606A/hu unknown
- 1995-07-13 ES ES95926564T patent/ES2180649T3/es not_active Expired - Lifetime
- 1995-07-13 BR BR9508323A patent/BR9508323A/pt not_active Application Discontinuation
- 1995-07-13 CN CN95195026A patent/CN1157569A/zh active Pending
- 1995-07-13 JP JP50495496A patent/JP4033485B2/ja not_active Expired - Fee Related
- 1995-07-13 RU RU97102350/14A patent/RU2155592C2/ru not_active IP Right Cessation
- 1995-07-13 DE DE69528654T patent/DE69528654T2/de not_active Expired - Lifetime
- 1995-07-13 WO PCT/SE1995/000856 patent/WO1996002258A1/en active IP Right Grant
-
1997
- 1997-01-06 IS IS4410A patent/IS1794B/is unknown
- 1997-01-17 FI FI970201A patent/FI970201A/fi unknown
- 1997-01-17 NO NO19970214A patent/NO310222B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69528654D1 (de) | 2002-11-28 |
| AU708758B2 (en) | 1999-08-12 |
| BR9508323A (pt) | 1998-01-06 |
| CA2194476C (en) | 2009-09-22 |
| IS4410A (is) | 1997-01-06 |
| DK0772446T3 (da) | 2002-11-25 |
| NZ290218A (en) | 1999-02-25 |
| EP0772446A1 (en) | 1997-05-14 |
| ES2180649T3 (es) | 2003-02-16 |
| DE69528654T2 (de) | 2003-03-13 |
| CN1157569A (zh) | 1997-08-20 |
| KR970704458A (ko) | 1997-09-06 |
| IS1794B (is) | 2001-12-12 |
| JP4033485B2 (ja) | 2008-01-16 |
| NO970214L (no) | 1997-01-17 |
| CZ287692B6 (en) | 2001-01-17 |
| CZ13997A3 (en) | 1997-07-16 |
| FI970201A0 (fi) | 1997-01-17 |
| NO970214D0 (no) | 1997-01-17 |
| HUT77606A (hu) | 1998-06-29 |
| SE9402529D0 (sv) | 1994-07-19 |
| KR100395723B1 (ko) | 2004-02-18 |
| ATE226439T1 (de) | 2002-11-15 |
| WO1996002258A1 (en) | 1996-02-01 |
| AU3089495A (en) | 1996-02-16 |
| JPH10502663A (ja) | 1998-03-10 |
| EP0772446B1 (en) | 2002-10-23 |
| HU9700161D0 (en) | 1997-03-28 |
| CA2194476A1 (en) | 1996-02-01 |
| RU2155592C2 (ru) | 2000-09-10 |
| MX9700442A (es) | 1997-04-30 |
| FI970201A (fi) | 1997-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO310222B1 (no) | Anvendelse av kitosan og et polysakkarid i forbindelse med sårheling | |
| EP0771206B1 (en) | Hard tissue stimulating agent | |
| US6486140B2 (en) | Agents, and methods employing them, for the prevention or reduction of tissue adhesion at a wound site | |
| KR100730527B1 (ko) | 히알루론산 겔 조성물과 그의 제조방법 및 그것을함유하는 의용 재료 | |
| US20060189516A1 (en) | Method for producing cross-linked hyaluronic acid-protein bio-composites | |
| RU2383336C2 (ru) | Биоматериалы, состоящие из сульфатированной гиалуроновой кислоты и геллана, применяемые для предотвращения спаек в позвоночнике | |
| TW574302B (en) | A method for producing cross-linked hyaluronic acid-protein bio-composites | |
| JP6203738B2 (ja) | 滅菌プロセス | |
| NZ511306A (en) | Cross-linked hyaluronic acids obtained by reaction of activated carboxy groups of hyaluronic acid (HY) with a polyamine | |
| JPH02500723A (ja) | コラーゲンとキトサンとグリコサミノグリカンとの混合物を基材とする新規な生体材料、その製造法及び人間の医薬にそれらの応用 | |
| WO2009049550A1 (fr) | Revêtement de support de vaisseau sanguin en polysaccharide d'amidoglucosane chargé en anticorps cd133 et son procédé de préparation | |
| WO2000016817A1 (en) | Dermal scaffold using neutralized chitosan sponge or neutralized chitosan/collagen mixed sponge | |
| Radhika et al. | Cellular proliferation on desamidated collagen matrices | |
| EP3517116A1 (en) | A cross-linked structure for tissue regeneration and engineering and the method for synthesising same | |
| AU696183C (en) | Hard tissue stimulating agent | |
| Russo et al. | Carbohydrates in Tissue Engineering | |
| Lan et al. | Swim bladder-derived biomaterials: structures, compositions, properties, modifications, and biomedical applications | |
| CN115245586A (zh) | 含海洋生物源的胶原蛋白-基材料及其制备方法 | |
| SUM | Development of chitin based materials for tissue engineering applications |